Biogen revenue and profit shrink on Aduhelm costs, slumping sales of multiple sclerosis therapies

Read Time:7 Second

The results come amid the rollout of Biogen and Eisai’s Leqembi, the first drug found to slow the progression of Alzheimer’s to win FDA approval.

About Post Author

Happy

0 %

Sad

0 %

Excited

0 %

Sleepy

0 %

Angry

0 %

Surprise

0 %

Olive Garden parent Darden Restaurants reported weaker-than-expected earnings and revenue for its fiscal first quarter.

Our companies' performances were reflective of the S&P 500 firms in aggregate.

Adobe reported third-quarter results on Thursday that beat Wall Street expectations for sales and earnings.

Oracle is projecting higher revenue and capital expenditures as its cloud-computing arm grows.

Investor concerns around the AI boom, coupled with the market's sensitivity to the Fed's next policy move, have caused Wall...

In late 2022, Goldman Sachs began to pivot away from its consumer operations, beginning a series of write-downs related to...